What are ARS Pharmaceuticals, Inc.'s total assets?

ARS Pharmaceuticals, Inc. (SPRY) holds $287.6M in total assets, down 12.1% year over year.

How much debt does ARS Pharmaceuticals, Inc. have?

ARS Pharmaceuticals, Inc. carries $96.5M in total debt against $61.3M of shareholders' equity, a debt-to-equity ratio of 1.57.

How much cash does ARS Pharmaceuticals, Inc. have?

ARS Pharmaceuticals, Inc. holds $24.3M in cash and equivalents.

Can ARS Pharmaceuticals, Inc. cover its short-term obligations?

Its current ratio is 4.94 — current assets exceed current liabilities.

Where does ARS Pharmaceuticals, Inc.'s balance sheet data come from?

Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ARS Pharmaceuticals, Inc. SPRY Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$41.32M-18.7%	$50.82M-28.4%	$70.97M-66.3%	$210.52M+250%
Short-term investments	$203.67M-22.6%	$263.21M+67.2%	$157.39M+146%	$63.86M—
Accounts receivable, net	$25.35M+210%	$8.18M—	$0—	——
Inventories	$23.05M+334%	$5.31M—	$0—	——
Prepaid expenses and other current assets	$31.62M+123%	$14.17M+22.6%	$11.56M-42.6%	$20.13M+56.8%
Total current assets	$284.9M-14.8%	$334.3M+44.3%	$231.73M-16.6%	$277.7M+357%
Property and equipment, net	$2.47M+131%	$1.07M+85.7%	$574K+74.5%	$329K+357%
Intangible assets, net	$14.45M+96.1%	$7.37M—	$0—	——
Other non-current assets	$2.79M-10.5%	$3.11M+388%	$638K-78.5%	$2.96M+12,774%
Total assets	$327.65M-6.7%	$351.15M+50.6%	$233.19M-17.1%	$281.44M+358%
Accounts payable	$37.95M+66.1%	$22.84M+960%	$2.15M-56.3%	$4.93M+137%
Accrued expenses	$588K+1,300%	$42K—	——	——
Deferred revenue	$609K+9.3%	$557K—	$0-100%	$283K-80.6%
Contract liabilities	$1.13M-26.2%	$1.53M—	$0-100%	$2.85M-4.7%
Total current liabilities	$39.15M+67.0%	$23.44M+880%	$2.39M-56.1%	$5.44M-33.5%
Long-term debt	$96.37M—	$0—	——	$0-100%
Total liabilities	$213.39M+126%	$94.36M+3,786%	$2.43M-71.6%	$8.55M-48.7%
Preferred stock	$0—	$0—	$0—	$0—
Common stock	$10K0.0%	$10K0.0%	$10K+11.1%	$9K+200%
Additional paid-in capital	$408.73M+7.6%	$379.87M+4.9%	$362M+3.6%	$349.41M+3,081%
Retained earnings	-$294.6M-139%	-$123.31M+6.1%	-$131.3M-70.7%	-$76.94M-82.1%
Accumulated other comprehensive income (loss)	$125K-43.2%	$220K+349%	$49K-88.0%	$407K—
Total stockholders' equity	$114.26M-55.5%	$256.8M+11.3%	$230.76M-15.4%	$272.89M+973%
Total liabilities and stockholders' equity	$327.65M-6.7%	$351.15M+50.6%	$233.19M-17.1%	$281.44M+358%
Inventory Current	$8.37M+60.6%	$5.21M—	——	——
Other intangible assets—net	$14.45M+96.1%	$7.37M—	$0—	——
Other Assets	$2.79M-10.5%	$3.11M+388%	$638K-78.5%	$2.96M+12,774%
Short-term investment securities (includes restricted investments of consolidated variable interest entities: 2026, $85; 2025, $84)	$203.67M-22.6%	$263.21M+67.2%	$157.39M+146%	$63.86M—
Accrued Progress Collections and Price Adjustments	$1.13M-26.2%	$1.53M—	$0-100%	$2.85M-4.7%
Accounts payable and other current liabilities (Note 11)	$37.95M+66.1%	$22.84M+960%	$2.15M-56.3%	$4.93M+58.7%
Other accrued liabilities	$588K+1,300%	$42K—	——	——
Contract Liabilities, Non-Current	$1.13M-26.2%	$1.53M—	$0-100%	$2.85M-4.7%
Deferred revenue, net of current portion	$1.13M-26.2%	$1.53M—	$0-100%	$2.85M-4.7%
Total debt	$96.37M+229,362%	$42K-84.7%	$274K-43.0%	$481K-95.5%
Common stock; $0.001 par value; 6,000 shares authorized; 3,755 and 3,751 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively	$10K0.0%	$10K0.0%	$10K+11.1%	$9K+200%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	$0—	$0—
Financing Liability	$72.14M+4.0%	$69.38M—	$0—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about ARS Pharmaceuticals, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are ARS Pharmaceuticals, Inc.'s total assets?: ARS Pharmaceuticals, Inc. (SPRY) holds $287.6M in total assets, down 12.1% year over year.
How much debt does ARS Pharmaceuticals, Inc. have?: ARS Pharmaceuticals, Inc. carries $96.5M in total debt against $61.3M of shareholders' equity, a debt-to-equity ratio of 1.57.
How much cash does ARS Pharmaceuticals, Inc. have?: ARS Pharmaceuticals, Inc. holds $24.3M in cash and equivalents.
Can ARS Pharmaceuticals, Inc. cover its short-term obligations?: Its current ratio is 4.94 — current assets exceed current liabilities.
Where does ARS Pharmaceuticals, Inc.'s balance sheet data come from?: Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.